Symposia are not sponsored, endorsed, or accredited by the American Academy of Pediatrics.
Schedule |
|
| * Times are PST | |
| 06:30 PM | Registration and Buffet Dinner |
| 06:45 PM | Case Presentation: It’s Just Nosebleeds…Or is it? |
| 06:45 PM | Welcome, Disclosures, Supporter Acknowledgement |
| 07:00 PM | Recognizing the Child who may have vWD |
| 07:15 PM | Diagnosing vWD: Current Best Practices |
| 07:30 PM | Management Across the Spectrum of vWD |
| 07:45 PM | Prophylaxis in vWD: Who, When, and Why? |
| 08:00 PM | Rapid-fire Case Presentations: When to Suspect vWD: Would you Test? |
| 08:15 PM | Audience Q&A |
| 08:30 PM | Adjourn and Online Evaluation |
Fernando Corrales-Medina, MD
Professor of Clinical Pediatrics
Director of the Hemophilia and Thrombosis Comprehensive Treatment Center
Medical Director for the Pediatric Hemophilia Program
Director of the Pediatric Hematology-Oncology Fellowship Program
University of Miami Miller School of Medicine
Miami, FL
Jessica Garcia, MD
Assistant Professor of Pediatrics
Division of Pediatric Hematology/Oncology
University of Texas Southwestern Medical Center
Dallas, TX
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
EXCEL Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Recognize clinical features and bleeding patterns that distinguish von Willebrand disease from other common pediatric causes of bleeding
- Apply evidence-based diagnostic strategies, such as bleeding assessment tools and appropriate laboratory testing, including assessment of iron status, to facilitate earlier diagnosis and referral for children with suspected von Willebrand disease
- Develop individualized management plans using current guideline recommendations and prophylactic treatment for appropriate patients
- Discuss current and investigational approaches that may expand future treatment options for pediatric patients with von Willebrand disease